Palatin Technologies, Inc. (PTN)
| Previous close | 1.7200 |
| Open | 1.8400 |
| Bid | 1.6500 x 1800 |
| Ask | 0.0000 x 3200 |
| Day's range | 1.7000 - 1.7482 |
| 52-week range | 1.4300 - 5.6500 |
| Volume | |
| Avg. volume | 700,080 |
| Market cap | 27.432M |
| Beta (5Y monthly) | 0.89 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Insider Monkey
10 Micro-Cap Healthcare Stocks Insiders Are Buying
In this article, we will take a detailed look at the 10 Micro-Cap Healthcare Stocks Insiders Are Buying. For a quick overview of such stocks, read our article 5 Micro-Cap Healthcare Stocks Insiders Are Buying. Investors have always been interested in the connection between insider buying and stock returns. Over the past several years there’s been a huge influx […]
- Zacks
Palatin (PTN) Up 15% on Results From Dry Eye Disease Study
A late-stage study data shows that treatment with Palatin's (PTN) experimental dry eye disease drug achieved statistically significant and clinically meaningful improvements across multiple symptom endpoints.
- Benzinga
Palatin Technologies Eyes Growing $6B Dry Eye Disease Market With Late-Stage Study Data
On Monday, Palatin Technologies Inc. (NYSE:PTN) announced the presentation of topline results for its Phase 3 PL9643 MELODY-1 trial, which evaluated the safety and efficacy of PL9643 versus vehicle in the treatment of dry eye disease (DED) at the American Society of Cataract and Refractive Surgery. The company released the mixed topline data in February 2024. The presentation included MELODY-1 Phase 3 data results, which indicate that the Intent-to-Treat PL9643 treatment population demonstrated
